IDT Biologika is a global biopharmaceutical contract development and manufacturing organization that specializes in the production of innovative live viral vaccines, viral vectors for gene and immune therapeutics, oncolytic viruses, and virus-like particles. They offer clients a single source CDMO partner with seamless end-to-end solutions and the ability to nimbly scale projects from development through to commercialization. This includes process development, drug substance manufacturing, sterile dosage filling, primary and secondary packaging, quality control, and analytics. IDT Biologika handles every step in manufacturing and packaging of small clinical batches and of large-scale commercial products.
The fully integrated services at their sites in the US and Germany are underscored by the commitment to quality and operational excellence that flows through their best-in-class process and cGMP (up to BSL3) manufacturing capabilities meeting FDA, EMA, and ANVISA standards. The company supplies their client’s products in vials, pre-filled syringes (with and without safety devices), autoinjectors, or as combination products.
IDT Biologika is unique in its ability to accommodate the development, testing, and manufacture of products for the world’s leading biopharmaceutical companies. Many human vaccines developed by IDT Biologika, together with international partners, are already in use, fighting infectious diseases such as COVID-19, tuberculosis, AIDS, malaria, cancer, dengue, and ebola.